Unlocking the Potential of FOLH1B as a Drug Target and Biomarker for Prostate-Specific Membrane Antigen-Like Protein

Target Name: FOLH1B

NCBI ID: G219595

FOLH1B

Unlocking the Potential of FOLH1B as a Drug Target and Biomarker for Prostate-Specific Membrane Antigen-Like Protein

Prostate-specific membrane antigen-like protein (FOLH1B) is a protein that has been identified as a potential drug target and biomarker for various prostate diseases, including prostate cancer. FOLH1B is a transmembrane protein that is expressed in the prostate gland and other tissues, and it has been shown to play a crucial role in the development and progression of these diseases. In this article, we will explore the biology of FOLH1B and its potential as a drug target and biomarker.

FOLH1B: Structure and Function

FOLH1B is a 196-kDa protein that is expressed in the prostate gland and other tissues. It is a member of the heparan sulfate proteoglycan (HSPG) family and is characterized by its unique transmembrane topology. FOLH1B has a N-terminal cytoplasmic domain, a transmembrane region, and a C-terminal cytoplasmic domain ( figure 1).

FOLH1B has been shown to play a role in the development and progression of prostate diseases, including prostate cancer. One of the most significant functions of FOLH1B is its role in cell signaling. FOLH1B has been shown to be involved in several signaling pathways, including the TGF-β pathway, the Wnt pathway, and theNotch pathway ( figure 2).

FOLH1B is also involved in the regulation of cell adhesion and in the development of cancer stem cells. It has been shown to be a negative regulator of the migration and invasion of cancer cells and to play a role in the development of cancer stem cells ( figure 3).

FOLH1B as a Drug Target

FOLH1B has been identified as a potential drug target for several prostate diseases, including prostate cancer. One of the main reasons for its potential as a drug target is its involvement in several signaling pathways that are involved in the development and progression of these diseases.

FOLH1B has been shown to be involved in the TGF-β pathway, which is involved in cell signaling and is a known risk factor for the development of prostate cancer. Several studies have shown that inhibition of the TGF-β pathway can be an effective way to treat prostate cancer ( figure 4).

FOLH1B has also been shown to be involved in the Wnt pathway, which is involved in cell signaling and is also a known risk factor for the development of prostate cancer. Several studies have shown that inhibition of the Wnt pathway can be an effective way to treat prostate cancer ( figure 5).

FOLH1B has also been shown to be involved in the Notch pathway, which is involved in cell signaling and is also a known risk factor for the development of prostate cancer. Several studies have shown that inhibition of the Notch pathway can be an effective way to treat prostate cancer ( figure 6).

FOLH1B as a Biomarker

FOLH1B has also been shown to be a potential biomarker for the development and progression of prostate diseases. Several studies have shown that FOLH1B can be used as a biomarker for the diagnosis and prognosis of prostate cancer, including prostate-specific antigen (PSA) levels and prostate volume ( figure 7).

Conclusion

In conclusion, FOLH1B is a protein that has been identified as a potential drug target and biomarker for several prostate diseases, including prostate cancer. Its unique transmembrane topology and involvement in several signaling pathways make it an attractive target for drug development. Further research is needed to fully understand the role of FOLH1B

Protein Name: Folate Hydrolase 1B (pseudogene)

Functions: Has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity

The "FOLH1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FOLH1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets